Last updated: September 7, 2026
Calaspargase pegol-mknl, marketed as Asparlas by Servier Pharmaceuticals, is a long-acting asparaginase used in multi-agent chemotherapy for acute lymphoblastic leukemia and lymphoblastic lymphoma. Its commercial position is supported by FDA approval, biologic exclusivity through approximately December 2030, and a differentiated every-three-week dosing schedule. Its market is narrow, specialist-driven, and largely dependent on pediatric oncology protocols rather than broad prescription demand.
Servier does not report Asparlas revenue as a standalone product. Public filings also do not provide a product-level forecast, unit volume, or operating margin. The most defensible financial assessment is therefore directional: Asparlas has a protected U.S. niche with recurring hospital demand, but its revenue ceiling is constrained by a small patient population, competition from pegaspargase and Erwinia-derived products, and the clinical need to switch patients because of hypersensitivity, thrombosis, pancreatitis, hepatotoxicity, or other toxicity.
What is calaspargase pegol-mknl and how does it work?
Calaspargase pegol-mknl is a PEGylated asparaginase enzyme. It depletes circulating asparagine, an amino acid that many lymphoblasts cannot synthesize effectively. The resulting amino-acid deprivation contributes to leukemic-cell death when the drug is used with other chemotherapy agents.
The drug is supplied as a 3,750-IU single-dose vial and is administered intravenously. The FDA-approved dosage is 2,500 international units per square meter every three weeks for patients from 1 month through 21 years of age with acute lymphoblastic leukemia or lymphoblastic lymphoma as part of a multi-agent chemotherapy regimen (FDA, 2023).
How does Asparlas differ from pegaspargase?
Calaspargase pegol-mknl and pegaspargase are both PEGylated forms of asparaginase. Their main commercial differentiator is dosing design and product availability rather than a fundamentally different treatment objective.
| Attribute |
Asparlas |
Oncaspar |
| Active enzyme |
Calaspargase pegol-mknl |
Pegaspargase |
| Manufacturer |
Servier |
Servier |
| FDA approval |
December 2018 |
1994 |
| Typical pediatric role |
Multi-agent treatment for ALL/LL |
Multi-agent treatment for ALL |
| Common labeled dosing interval |
Every 3 weeks |
Regimen-dependent |
| Administration |
Intravenous infusion |
Intravenous or intramuscular use, depending on product labeling |
| Regulatory status |
Biologic license application |
Biologic license application |
| Main commercial advantage |
Long dosing interval and U.S. supply option |
Established clinical use and broad historical adoption |
Asparlas was developed in part to provide a longer-acting asparaginase option with a more predictable supply position than certain prior products. Its clinical value is greatest in protocols that require sustained asparaginase exposure while limiting the number of administrations.
What is the FDA regulatory status of Asparlas?
The FDA approved Asparlas on December 22, 2018, for use as part of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia and lymphoblastic lymphoma in patients aged 1 month to 21 years (FDA, 2018).
Key regulatory milestones are as follows:
| Date |
Event |
| December 2018 |
FDA approval of calaspargase pegol-mknl |
| 2018 |
Approval based on pharmacokinetic and pharmacodynamic comparability data versus pegaspargase, with clinical support from the treatment setting |
| 2021 onward |
Expanded competitive environment following FDA approval of Erwinase-related replacement therapy Rylaze |
| 2023 |
Current U.S. prescribing information continued to identify Asparlas for pediatric and young-adult ALL/LL treatment |
The product is not a conventional small-molecule generic. A competing product would require an abbreviated pathway for a biologic, generally through a biosimilar or interchangeable biosimilar application under the Public Health Service Act. That pathway requires analytical, pharmacokinetic, immunogenicity and, where necessary, additional clinical evidence.
When does calaspargase pegol-mknl lose exclusivity?
The principal U.S. regulatory protection is the 12-year reference-product exclusivity period for a licensed biologic. Based on the December 2018 first licensure date, the core biologic exclusivity period is expected to run until approximately December 2030, subject to the statutory calculation and any applicable pediatric extension.
FDA biologic exclusivity prevents approval of a biosimilar application for 12 years after first licensure. It does not prevent all forms of competition during that period, and it does not eliminate patent-based litigation risk after approval of a biosimilar application.
| Protection |
Estimated or statutory endpoint |
Commercial effect |
| FDA biologic reference-product exclusivity |
Approximately December 2030 |
Blocks biosimilar approval based on the reference product before the statutory date |
| Pediatric exclusivity |
No clear public indication that a six-month extension has been granted |
Could extend applicable listed protection if awarded |
| Patent protection |
Patent-specific; must be evaluated by claim and jurisdiction |
Can delay or shape biosimilar launch beyond regulatory exclusivity |
| Orphan-drug exclusivity |
No clear basis to treat Asparlas as an orphan-exclusivity product |
Not assumed in the base case |
The key financial implication is that Asparlas should remain insulated from U.S. biosimilar price erosion before the early 2030s unless a separate legal or regulatory pathway produces an earlier competing product.
What patents protect Asparlas?
The commercial protection for Asparlas is likely to be based on a combination of biologic exclusivity, patents covering PEGylated asparaginase compositions and manufacturing processes, and possible method-of-use claims. Patent protection cannot be summarized reliably by a single expiration date because claim scope, terminal disclaimers, patent-term adjustment, continuations and litigation outcomes affect the effective barrier.
The relevant patent analysis should distinguish four categories:
- Composition patents covering the modified asparaginase molecule.
- Formulation patents covering storage, concentration, excipients or stability.
- Manufacturing patents covering conjugation, purification or production methods.
- Method-of-use patents covering dosing, treatment schedules or patient populations.
For Asparlas, manufacturing and analytical-control barriers may be more important than a simple formulation patent. PEGylated enzymes can be difficult to replicate closely because commercial equivalence depends on PEG conjugation distribution, enzyme activity, impurities, aggregation, stability and immunogenicity.
How strong is the Asparlas patent estate?
The estate is commercially meaningful but not easily characterized as impenetrable. Biologic exclusivity is the stronger near-term barrier. Patent strength after 2030 will depend on whether Servier has enforceable claims that cover the commercial molecule, production method or clinically relevant dosing regimen.
A biosimilar sponsor could pursue:
- A non-infringement position based on a different manufacturing process.
- An invalidity challenge against composition or process claims.
- A license or settlement with a delayed launch.
- A product that relies on the same reference product while contesting listed patents.
- A launch after regulatory exclusivity but before expiration of selected secondary patents, if the sponsor accepts litigation risk.
No major public patent settlement involving a U.S. Asparlas biosimilar was identified in the public record available through June 2024. The absence of a reported settlement does not establish that no confidential commercial arrangement exists.
What is the Orange Book and Purple Book status of Asparlas?
Asparlas is a biologic, so its principal FDA reference is the Purple Book rather than the Orange Book. The Orange Book covers approved drug products, including many small molecules, while the Purple Book identifies licensed biological products and biosimilar relationships.
The commercial consequences are direct:
- Generic-drug substitution rules do not apply to Asparlas in the same way they apply to an Orange Book-listed small molecule.
- A biosimilar must receive FDA approval under the biologics pathway.
- Interchangeability, if granted, would depend on a separate FDA determination.
- Hospital formulary decisions remain important because oncologists may select among asparaginase products based on protocol, supply, prior reaction and institutional practice.
How large is the market for calaspargase pegol-mknl?
The addressable market is concentrated in pediatric and young-adult hematologic oncology. The United States records roughly 3,000 new pediatric acute lymphoblastic leukemia cases annually, although the exact number varies by age range and source (National Cancer Institute, 2024). Asparaginase is used during defined treatment phases, not continuously over the life of the patient.
Market demand depends on:
- New ALL and lymphoblastic lymphoma diagnoses.
- Protocol selection by cooperative groups and hospitals.
- Patient body-surface area.
- Number of planned doses.
- Treatment completion rates.
- Switching caused by hypersensitivity or toxicity.
- Product shortages and allocation practices.
- Use in adolescents and young adults up to age 21.
The market is therefore volume-limited but relatively recurring. Every newly diagnosed patient entering a protocol can generate multiple doses, while treatment centers often purchase through specialty distribution or hospital channels.
Who competes with Asparlas?
| Competitor |
Product |
Competitive position |
| Servier |
Oncaspar, pegaspargase |
Established PEGylated asparaginase with long clinical history |
| Jazz Pharmaceuticals historically, Servier ownership context |
Erwinaze, asparaginase Erwinia chrysanthemi |
Used especially after hypersensitivity to E. coli-derived products; supply and administration burden have been important issues |
| Jazz Pharmaceuticals |
Rylaze, asparaginase erwinia chrysanthemi recombinant |
FDA-approved replacement option for patients who develop hypersensitivity to long-acting E. coli-derived asparaginase |
| Emerging biosimilars |
None publicly established in the U.S. market through June 2024 |
Potential post-2030 price competition |
Rylaze is the most important modern competitive development because it gives treatment centers another option for patients who cannot continue with Asparlas or Oncaspar. It is not a direct substitute for every patient because its dosing frequency and clinical use differ.
What drives Asparlas revenue?
Asparlas revenue is driven more by treatment protocol penetration and product mix than by broad market expansion.
The principal revenue drivers are:
Protocol adoption
If major pediatric oncology protocols specify or favor calaspargase pegol-mknl, Servier can capture recurring demand from treatment centers. Protocol familiarity lowers switching costs and supports continued use.
Dose intensity
Revenue rises with the number of completed doses per patient. It falls when patients discontinue treatment because of allergy, pancreatitis, thrombosis, liver toxicity or other adverse events.
Product availability
Asparaginase supply has historically been strategically important because treatment delays can affect clinical protocols. Reliable supply can shift market share even when products are clinically comparable.
Hospital purchasing
The product is administered in hospitals and oncology centers. Net sales depend on contracting, group purchasing organizations, payer reimbursement, charge capture and inventory management rather than retail prescription volume.
Pediatric oncology concentration
The limited number of treatment centers makes the market commercially efficient to cover, but it also concentrates buyer power. Large institutions can influence product selection and negotiate pricing.
What is the financial trajectory for Asparlas?
Servier is a privately held pharmaceutical company and does not provide the same product-level quarterly reporting as a public U.S. biopharmaceutical company. Public materials do not disclose standalone Asparlas revenue, gross-to-net deductions, contribution margin, or U.S. market share.
The most supportable financial trajectory is:
| Period |
Expected commercial profile |
| 2018-2020 |
Launch and protocol adoption; market entry supported by the need for an additional long-acting asparaginase |
| 2021-2024 |
Mature niche growth, with competition from Rylaze and continued use alongside Oncaspar |
| 2025-2030 |
Stable protected revenue base, dependent on protocol retention, supply reliability and pricing |
| Around 2030 onward |
Increased biosimilar and patent-litigation risk; potential price compression and contracting pressure |
| Post-2030 |
Revenue decline risk depends on biosimilar timing, interchangeability, patent outcomes and physician switching |
A reasonable investment view is that Asparlas is a durable specialty-oncology asset rather than a high-growth blockbuster. Its revenue is likely to be resilient before biologic exclusivity expires, but the product has a finite market and limited opportunity to expand beyond the asparaginase component of ALL treatment.
No credible public basis supports assigning a specific annual revenue figure to Asparlas without relying on unsupported assumptions about net price, patient share and dose utilization.
What generic or biosimilar launch risks exist?
The principal launch risk begins around the early 2030s, not immediately. A biosimilar sponsor would face several barriers:
- Limited patient population and concentrated hospital demand.
- Complex characterization of PEGylated enzyme structure.
- Immunogenicity and hypersensitivity concerns.
- Need to establish pharmacokinetic and pharmacodynamic similarity.
- Manufacturing consistency requirements.
- Potential patent litigation.
- Difficulty achieving rapid formulary conversion in pediatric oncology.
- Clinical reluctance to switch stable patients from a familiar product.
Price erosion may also be less severe than in large primary-care biologic markets if there are only one or two entrants. The first biosimilar could gain share through contracting, while later entrants could intensify discounting.
What litigation and settlement issues affect Asparlas?
The likely legal pressure points are patent challenges filed by biosimilar applicants after the reference product becomes eligible for a biosimilar pathway. Potential disputes would focus on:
- Whether claims cover the commercial calaspargase molecule.
- Whether manufacturing claims are infringed by a different process.
- Whether formulation claims remain valid and commercially relevant.
- Patent-term adjustment and expiration calculations.
- Launch timing under the Biologics Price Competition and Innovation Act.
- Antitrust exposure if a settlement includes a delayed-entry date or commercial restrictions.
Through June 2024, no major publicly reported U.S. Paragraph IV case applied directly to Asparlas because Paragraph IV is an abbreviated new drug application mechanism for small-molecule generics. The analogous future dispute would involve a biosimilar applicant’s patent certifications and the BPCIA patent-exchange process.
How does Asparlas compare with other asparaginase products?
| Factor |
Asparlas |
Oncaspar |
Rylaze |
| Enzyme source |
E. coli-derived asparaginase |
E. coli-derived asparaginase |
Recombinant Erwinia chrysanthemi |
| Dosing convenience |
Long-acting, every-three-week schedule |
Long-acting |
More frequent administration |
| Use after hypersensitivity |
Usually limited if reaction is to E. coli-derived products |
Usually limited if reaction is to E. coli-derived products |
Important alternative |
| Market role |
Front-line or protocol-selected long-acting option |
Established comparator |
Rescue or substitution option |
| Main commercial risk |
Post-2030 biosimilar competition |
Mature competition and substitution |
Administration burden and cost |
Asparlas competes most effectively when clinicians value long dosing intervals and supply reliability. Rylaze is more complementary than directly substitutive because it addresses a different clinical need: maintaining asparaginase therapy after allergy or inactivation associated with E. coli-derived products.
What geographic markets matter for calaspargase pegol-mknl?
The United States is the clearest commercial market because FDA approval established a defined pediatric indication and Servier has a U.S. oncology presence. International opportunity depends on country-specific approvals, reimbursement, pediatric oncology protocols and access to specialist hospitals.
Geographic expansion is constrained by:
- Small patient populations in each country.
- National health technology assessment requirements.
- Hospital-based procurement.
- Different cooperative-group treatment protocols.
- Local reimbursement for high-cost oncology medicines.
- Cold-chain and specialty-distribution requirements.
The United States should remain the central value driver unless Servier reports meaningful uptake in Europe or other large oncology markets.
Key Takeaways
- Asparlas is a protected, specialist biologic for pediatric and young-adult ALL and lymphoblastic lymphoma.
- FDA approval occurred in December 2018.
- Core U.S. biologic exclusivity is expected to run until approximately December 2030.
- Servier does not disclose standalone Asparlas revenue, margin or market share.
- The product’s commercial value comes from protocol-driven recurring demand, long dosing intervals and hospital oncology use.
- Oncaspar is the closest established comparator; Rylaze is the main alternative for hypersensitivity-related treatment changes.
- No conventional generic pathway applies. Future competition will come through biosimilars and potentially patent challenges.
- The key post-2030 risks are biosimilar entry, contracting pressure, patent litigation and formulary substitution.
- Asparlas is best characterized as a durable niche oncology asset with limited volume expansion and meaningful pre-2030 protection.
FAQs
Is calaspargase pegol-mknl a biosimilar?
No. Calaspargase pegol-mknl is an original FDA-licensed biologic product, not a biosimilar to pegaspargase.
Is Asparlas interchangeable with Oncaspar?
FDA interchangeability is a specific regulatory designation. Asparlas should not be treated as automatically interchangeable with Oncaspar merely because both are PEGylated asparaginase products.
Does Asparlas have orphan-drug exclusivity?
Publicly available regulatory information does not establish orphan-drug exclusivity as the principal protection for Asparlas. Its primary protection is FDA biologic exclusivity combined with any applicable patents.
What is the biggest clinical risk to Asparlas sales?
The largest near-term risk is loss of use after hypersensitivity, inactivation or treatment-limiting toxicity. The largest long-term risk is biosimilar competition after the biologic exclusivity period.
Can hospitals substitute a biosimilar for Asparlas automatically?
Automatic substitution would depend on the biosimilar’s FDA designation, state law, payer policy and institutional formulary rules. A biosimilar approval alone does not guarantee automatic pharmacy substitution.
References
-
Food and Drug Administration. (2018, December 22). FDA approves calaspargase pegol-mknl for acute lymphoblastic leukemia. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2023). Asparlas (calaspargase pegol-mknl) prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2021). FDA approves recombinant erwinia asparaginase for acute lymphoblastic leukemia. U.S. Department of Health and Human Services.
-
National Cancer Institute. (2024). Childhood acute lymphoblastic leukemia treatment. National Institutes of Health.
-
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003, 124 Stat. 119.
